Heidi Cuthbert

Recon Technology (NASDAQ:RCON) reported a significant improvement in its financial performance for the first six months of fiscal year 2026, ending December 31, 2025.

bioAffinity Technologies (NASDAQ:BIAF) reported fiscal year 2025 results that underscore an aggressive transition from a broad laboratory service model to a specialized, high-growth diagnostic powerhouse focused on early-stage lung cancer detection.

The ONE Group Hospitality (NASDAQ:STKS) reported a complex fourth quarter for fiscal 2025, marked by a strategic contraction of its portfolio and a calendar shift that dampened its traditional holiday revenue peak.

Voyager Acquisition (NASDAQ:VACH) moved one step closer to finalizing its merger with Veraxa Biotech following an extraordinary general meeting on March 12, 2026.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has secured a long-term financial runway, shifting focus toward pivotal data readouts for its lead gastrointestinal program following a successful fourth quarter and a transformative February financing.

Bitcoin climbed to its highest level in a week even as global equities declined and oil prices surged amid escalating tensions in the Middle East.

Hong Kong regulators are reportedly preparing to grant the city’s first stablecoin licences, with HSBC, Anchorpoint and OSL Group among the three institutions shortlisted.

Ripple has launched a new share buyback programme that could increase its valuation to about $50 billion, representing a roughly 20% jump from its previous funding round.

The US Commodity Futures Trading Commission has launched a rulemaking process on prediction markets, asking the public to comment on how federal derivatives law should apply to event-based contracts.

Precision BioSciences (NASDAQ:DTIL) reported a sharp swing to profitability in its final quarter of 2025, a result primarily driven by the recognition of deferred revenue from its heavyweight partnerships in the genome-editing space.